Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K)
Objectives Patients with end-stage renal disease (ESRD) on hemodialysis (HD) are at risk for hyperkalemia (HK), associated with cardiac arrhythmia and sudden death. Data on the burden of HK and management techniques among HD patients in China are still scarce. This study assessed the treatment modal...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2384585 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850140143030108160 |
|---|---|
| author | Haijiao Jin Renhua Lu Lihong Zhang Li Yao Guojian Shao Li Zuo Shuguang Qin Xinzhou Zhang Qinghong Zhang Weimin Yu Qun Luo Yuqing Ren Hui Peng Jie Xiao Qiongqiong Yang Qinkai Chen Yifan Shi Zhaohui Ni |
| author_facet | Haijiao Jin Renhua Lu Lihong Zhang Li Yao Guojian Shao Li Zuo Shuguang Qin Xinzhou Zhang Qinghong Zhang Weimin Yu Qun Luo Yuqing Ren Hui Peng Jie Xiao Qiongqiong Yang Qinkai Chen Yifan Shi Zhaohui Ni |
| author_sort | Haijiao Jin |
| collection | DOAJ |
| description | Objectives Patients with end-stage renal disease (ESRD) on hemodialysis (HD) are at risk for hyperkalemia (HK), associated with cardiac arrhythmia and sudden death. Data on the burden of HK and management techniques among HD patients in China are still scarce. This study assessed the treatment modalities, recurrence, and prevalence of HK in Chinese HD patients.Methods In this prospective cohort study conducted from May 2021 to July 2022, patients aged ≥18 years who had ESRD and were on HD were enrolled from 15 centers in China (up to 6 months).Results Overall, 600 patients were enrolled. At the baseline visit, mean (± standard deviation) urea reduction ratio was 68.0% ± 9.70 and Kt/V was 1.45 ± 0.496. Over 6 months, 453 (75.5%) patients experienced HK, of whom 356 (78.6%) recurred. Within 1, 2, 3, 4, 5, and 6 months, 203 (44.8%), 262 (57.8%), 300 (66.2%), 326 (72.0%), 347 (76.6%), and 356 (78.6%) patients had at least one HK recurrence event, respectively. The proportions of patients with ≥1, 2, 3, 4, 5, or 6 HK recurrence events were 356 (78.6%), 306 (67.5%), 250 (55.2%), 208 (45.9%), 161 (35.5%), and 110 (24.3%), respectively. Among the 453 patients who experienced HK, only 24 (5.3%) were treated with potassium binders: seven (1.5%) with sodium polystyrene sulfonate, 13 (2.9%) with calcium polystyrene sulfonate, and six (1.3%) with sodium zirconium cyclosilicate.Conclusion Since HK is a chronic illness, long-term care is necessary. Patients on HD should have effective potassium management on non-dialysis days, yet our real-world population rarely used potassium binders.Trial registration ClinicalTrials.gov Identifier NCT04799067 |
| format | Article |
| id | doaj-art-c5e36a4796e74b1caaf3ecf4db15dac6 |
| institution | OA Journals |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-c5e36a4796e74b1caaf3ecf4db15dac62025-08-20T02:29:56ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146210.1080/0886022X.2024.2384585Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K)Haijiao Jin0Renhua Lu1Lihong Zhang2Li Yao3Guojian Shao4Li Zuo5Shuguang Qin6Xinzhou Zhang7Qinghong Zhang8Weimin Yu9Qun Luo10Yuqing Ren11Hui Peng12Jie Xiao13Qiongqiong Yang14Qinkai Chen15Yifan Shi16Zhaohui Ni17Department of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nephrology, The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Nephrology, The First Hospital of China Medical University, Shenyang, Liaoning, ChinaDepartment of Nephrology, Wenzhou Central Hospital, Wenzhou, Zhejiang, ChinaDepartment of Nephrology, Peking University People’s Hospital, Beijing, ChinaDepartment of Nephrology, Guangzhou First People’s Hospital, Guangzhou, Guangdong, ChinaDepartment of Nephrology, Shenzhen People’s Hospital, Shenzhen, Guangdong, ChinaDepartment of Nephrology, Taihe Hospital, Shiyan, Hubei, ChinaDepartment of Nephrology, Shanxi Bethune Hospital, Taiyuan, Shanxi, ChinaDepartment of Nephrology, Hwa Mei Hospital, University of Chinese Academy of Sciences, Ningbo, Zhejiang, ChinaDepartment of Nephrology, Yangquan Coal Industry (Group) General Hospital, Yangquan, Shanxi, ChinaDepartment of Nephrology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, ChinaDepartment of Nephrology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, ChinaDepartment of Nephrology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, ChinaDepartment of Nephrology, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, ChinaMedical Affairs, AstraZeneca Investment China Co, Shanghai, ChinaDepartment of Nephrology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaObjectives Patients with end-stage renal disease (ESRD) on hemodialysis (HD) are at risk for hyperkalemia (HK), associated with cardiac arrhythmia and sudden death. Data on the burden of HK and management techniques among HD patients in China are still scarce. This study assessed the treatment modalities, recurrence, and prevalence of HK in Chinese HD patients.Methods In this prospective cohort study conducted from May 2021 to July 2022, patients aged ≥18 years who had ESRD and were on HD were enrolled from 15 centers in China (up to 6 months).Results Overall, 600 patients were enrolled. At the baseline visit, mean (± standard deviation) urea reduction ratio was 68.0% ± 9.70 and Kt/V was 1.45 ± 0.496. Over 6 months, 453 (75.5%) patients experienced HK, of whom 356 (78.6%) recurred. Within 1, 2, 3, 4, 5, and 6 months, 203 (44.8%), 262 (57.8%), 300 (66.2%), 326 (72.0%), 347 (76.6%), and 356 (78.6%) patients had at least one HK recurrence event, respectively. The proportions of patients with ≥1, 2, 3, 4, 5, or 6 HK recurrence events were 356 (78.6%), 306 (67.5%), 250 (55.2%), 208 (45.9%), 161 (35.5%), and 110 (24.3%), respectively. Among the 453 patients who experienced HK, only 24 (5.3%) were treated with potassium binders: seven (1.5%) with sodium polystyrene sulfonate, 13 (2.9%) with calcium polystyrene sulfonate, and six (1.3%) with sodium zirconium cyclosilicate.Conclusion Since HK is a chronic illness, long-term care is necessary. Patients on HD should have effective potassium management on non-dialysis days, yet our real-world population rarely used potassium binders.Trial registration ClinicalTrials.gov Identifier NCT04799067https://www.tandfonline.com/doi/10.1080/0886022X.2024.2384585End-stage renal diseasehemodialysishyperkalemiainterdialytic intervalpotassium binders |
| spellingShingle | Haijiao Jin Renhua Lu Lihong Zhang Li Yao Guojian Shao Li Zuo Shuguang Qin Xinzhou Zhang Qinghong Zhang Weimin Yu Qun Luo Yuqing Ren Hui Peng Jie Xiao Qiongqiong Yang Qinkai Chen Yifan Shi Zhaohui Ni Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K) Renal Failure End-stage renal disease hemodialysis hyperkalemia interdialytic interval potassium binders |
| title | Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K) |
| title_full | Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K) |
| title_fullStr | Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K) |
| title_full_unstemmed | Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K) |
| title_short | Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K) |
| title_sort | hyperkalemia burden and treatment patterns in chinese patients on hemodialysis final analysis of a prospective multicenter cohort study precede k |
| topic | End-stage renal disease hemodialysis hyperkalemia interdialytic interval potassium binders |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2384585 |
| work_keys_str_mv | AT haijiaojin hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT renhualu hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT lihongzhang hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT liyao hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT guojianshao hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT lizuo hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT shuguangqin hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT xinzhouzhang hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT qinghongzhang hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT weiminyu hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT qunluo hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT yuqingren hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT huipeng hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT jiexiao hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT qiongqiongyang hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT qinkaichen hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT yifanshi hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek AT zhaohuini hyperkalemiaburdenandtreatmentpatternsinchinesepatientsonhemodialysisfinalanalysisofaprospectivemulticentercohortstudyprecedek |